Thomas Grader‐Beck

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Simon Bowman, Robert I. Fox, Thomas Dörner et al. · The Lancet · 2021 · 201 citations · Full text

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +12

Ocular and Systemic Morbidity in a Longitudinal Cohort of Sjögren’s Syndrome

Esen K. Akpek, Priya M. Mathews, Sarah Hahn et al. · Ophthalmology · 2014 · 112 citations

Rheumatology, Ocular Disease, Autoimmune Disease +9

cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression

Thomas Grader‐Beck, André A. F. L. van Puijenbroek, Lee M. Nadler et al. · Blood · 2003 · 49 citations · Full text

Ocular Complications of Primary Sjögren Syndrome in Men

Priya M. Mathews, Sarah Hahn, Michelle Hessen et al. · American Journal of Ophthalmology · 2015 · 40 citations

Rheumatology, Ocular Disease, Ophthalmology +5

Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study

Benjamin A. Fisher, Xavier Mariette, Athena Papas et al. · The Lancet · 2024 · 39 citations · Full text

Rheumatology, Subcutaneous Iscalimab, Week 24 +6